Affymetrix, Thermo Fisher Rebuff Origin Technologies Purchase Offer | GenomeWeb

This story has been updated with new information from a letter released today from Origin Technologies to Affymetrix demonstrating an increased financing committment and adressing other concerns.

NEW YORK (GenomeWeb) – An offer by former Affymetrix executives to buy the company under a newly formed shell corporation — and to pay off the cancellation penalties of Thermo Fisher Scientific's previously announced proposal to acquire Affy — has triggered a call and response between Affy, Thermo, and the newcomer Origin Technologies this week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.